Banner Image: Teenage Girl With Classmates

Results with Qelbree

Qelbree is a nonstimulant treatment for ADHD in children ages 6-17 that is effective all day. Qelbree has been proven effective and safe* in clinical trials, and may be the right treatment option for your child.

*Important: Monitor your child for mood or behavior changes. Your child’s doctor may also monitor for changes in blood pressure and heart rate.

Proven results  

Safety profile  

Qelbree is proven to significantly reduce ADHD symptoms in 3 clinical trials


In clinical studies, Qelbree—a nonstimulant—was proven to help effectively manage ADHD symptoms.

Icon: Clock

Rapid and extended release for full-day coverage.

By reducing the impact of ADHD symptoms, Qelbree can help improve your child's difficult behavior related to ADHD. Qelbree met the goal of 3 different clinical trials – a significant reduction in ADHD symptom scores in 6 weeks. For some patients, Qelbree reduced ADHD symptom scores as early as week 1.

Your child’s doctor can recommend Qelbree as part of a total treatment program that may include counseling and support therapies.

In one study of children 6-11 years of age, ADHD symptom score reductions were statistically significant for 100 mg and 200 mg doses, beginning at week 1. In a second study of adolescents 12-17 years of age, ADHD symptom score reductions were statistically significant for 400 mg, beginning at week 2.

Icon: Graph

Clinical Trial Results

How we ran the studies:
Qelbree was studied in three clinical trials involving boys and girls ages 6-17 who had been diagnosed with ADHD.

The studies measured what kind of changes in ADHD symptoms these children experienced over the course of the six- to eight-week clinical trials. They measured the frequency and severity of ADHD symptoms, including inattention, hyperactivity, and impulsivity.

Arrow Pink

Qelbree showed significant reduction in symptoms compared to placebo.

Qelbree was also consistently proven to be effective and safe in multiple clinical studies in over 800 patients with a once-a-day convenient dose.

Image: Two Friends Laughing

A school routine that’s

achievable

Proven results  

Safety profile  

Qelbree is proven to be safe*, with manageable side effects


In clinical trials, Qelbree was consistently proven to be a safe and effective treatment for ADHD, with a low incidence of side effects.

*Important: Monitor your child for mood or behavior changes. Your child’s doctor may also monitor for changes in blood pressure and heart rate.

The majority of these side effects did not cause children to stop treatment with Qelbree.

Icon: Pills

Qelbree is not a controlled substance and there was no evidence of abuse.

Sometimes parents consider a planned break or "drug holiday" from a medication due to side effects. This is a conversation you should have with your child and with their doctor before considering a break.

Qelbree is unlikely to have any negative interactions with stimulants like methylphenidate and amphetamine.

Most Common Side Effects

Side effect

Placebo

Qelbree

 

Somnolence (drowsiness)

4%

16%

Decreased appetite

0.4%

7%

Tiredness

2%

6%

Nausea

3%

5%

Vomiting

2%

4%

Irritability

1%

3%

Trouble sleeping§

1%

4%

Somnolence: somnolence, lethargy, sedation

§Trouble sleeping: initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia.

Only 3% of participants taking Qelbree discontinued the clinical trial due to side effects, while 1% of those taking the placebo discontinued the clinical trial.

Savings and Resources

Learn more about the resources available to you with Qelbree.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

QelbreeTM (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in children ages 6 to 17.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment [read more] or when the dose is changed. Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment or when the dose is changed. [read more] Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

Your child should not take Qelbree if they:
Take a medicine for depression called monoamine oxidase inhibitor (MAOI), or stopped taking an MAOI in the last 14 days. Also, your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your child’s doctor if they show any signs of mania.

Do not let your teen drive or operate heavy machinery until you know how Qelbree will affect them. Qelbree may cause your teen to feel sleepy or tired.

The most common side effects of Qelbree include sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability. These are not all the possible side effects of Qelbree.

You may report negative side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see Medication Guide including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

QelbreeTM (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in children ages 6 to 17.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment [read more] or when the dose is changed. Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment or when the dose is changed. [read more] Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

Your child should not take Qelbree if they:
Take a medicine for depression called monoamine oxidase inhibitor (MAOI), or stopped taking an MAOI in the last 14 days. Also, your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your child’s doctor if they show any signs of mania.

Do not let your teen drive or operate heavy machinery until you know how Qelbree will affect them. Qelbree may cause your teen to feel sleepy or tired.

The most common side effects of Qelbree include sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability. These are not all the possible side effects of Qelbree.

You may report negative side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see Medication Guide including Boxed Warning.